$248 Million

Passage Bio

Initial Public Offering

Bookrunner, February 2020

Passage Bio
Passage Bio, Inc. is a genetic medicines company focused on the development of transformative therapies to treat rare, monogenic central nervous system (CNS) diseases with a high unmet medical need.